Ceritinib(also known as LDK 378, Zykadia) is an anaplastic lymphoma kinase (ALK)-positive inhibitor primarily used for the treatment of metastatic non-small cell lung cancer (NSCLC).
Synthesis, Structure–Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials.
ALK inhibitors in non-small cell lung cancer: crizotinib and beyond.
Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK.
ALK inhibitors in non-small cell lung cancer: the latest evidence and developments.
 T.H.Marsilje, et al, J. Med. Chem., 2013, 56(14), pp 5675-5690.